ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
DeepLNM: A Multimodal Model for Predicting Lymph Node Metastasis in Colorectal Cancer.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07239063 (Validation of a High-Throughput, Large-Format, Tissue-Specific Preprocessing Protocol for Lung and Colorectal Cancer), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Validation of a High-Throughput, Large-Format, Tissue-Specific Preprocessing Protocol for Lung and Colorectal Cancer
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Funding
Abstract
Accurate assessment of lymph node metastasis (LNM) is critical for prognostic stratification and treatment selection in colorectal cancer (CRC), yet imaging and routine pathology can yield false-negative/false-positive results. We propose DeepLNM, a multi-center foundation model for LNM prediction in CRC, evaluated with retrospective, external, prospective, and user study evidence. A multimodal dataset was assembled from three hospitals, with matched hematoxylin and eosin (H&E)-stained whole-slide images (WSI), CT scans, and text. DeepLNM achieved a mean AUC of 0.922 in the internal cohort and AUCs of 0.872 and 0.848 in two external cohorts. In a prospective cohort from a registered clinical trial (NCT07239063), DeepLNM remained robust (AUC = 0.845). In a user study, DeepLNM improved diagnostic accuracy, especially for junior pathologists (95.0%-97.3%), while reducing diagnostic time and increasing confidence. To explore the model's generalizability, it was further validated in a gastric cancer cohort, achieving an AUC of 0.793. Finally, DeepLNM identified histopathological features associated with LNM, addressing the "black-box" concern of deep learning. Together, these results position DeepLNM as a clinically preliminarily validated multimodal model for predicting LNM status in CRC, potentially facilitating the clinical translation of AI pathology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.